RxDoctor Payments Data

Bishoy Labib, MD

Neurology · Palm Desert, CANPI 1992723605

Payments from drug & device makers

$16,746in general payments, 2019–2025

Across 684 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • Eisai Inc.$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • UCB, Inc.$1K
  • Acadia Pharmaceuticals Inc$737
  • plus $9K from 52 others

What the payments were for

  • Speaking & faculty fees$420%
  • Food & beverage$16,59599%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen76$1,549
Eisai Inc.58$1,445
AstraZeneca(2 entities)48$1,249
AbbVie(2 entities)65$1,160
UCB, Inc.39$1,147
Acadia Pharmaceuticals Inc30$737
Neurocrine Biosciences, Inc.26$700
Lundbeck LLC25$621
Amneal Pharmaceuticals LLC20$608
Teva Pharmaceuticals USA, Inc.23$589
MDD US Operations, LLC25$515
Kyowa Kirin, Inc.22$511
Lilly USA, LLC15$370
SK Life Science, Inc.11$358
CSL Behring12$331
Genentech USA, Inc.10$317
Amgen14$315
Takeda Pharmaceuticals U.S.A., Inc.9$284
Tanabe Pharma America, Inc.11$254
Pfizer12$241
Novo Nordisk2$237
Novartis13$234
Akcea Therapeutics, Inc.6$214
Otsuka America Pharmaceutical, Inc.7$189
Catalyst Pharmaceuticals, Inc.6$170
Nevro Corp.3$168
Abbott5$158
Biohaven Pharmaceuticals, Inc.8$158
Argenx US, Inc.6$156
Adamas Pharmaceuticals, Inc.7$145
Sanofi7$144
Johnson & Johnson(2 entities)6$132
Ipsen Biopharmaceuticals, Inc5$128
Mallinckrodt Hospital Products Inc.5$127
EMD Serono, Inc.4$106
Avanir Pharmaceuticals, Inc.4$91
EDW Pharma, Inc.1$89
Neurelis, Inc.3$84
GE HealthCare3$74
Amylyx Pharmaceuticals, Inc.3$73
Harmony Biosciences LLC2$60
Grifols USA, LLC2$54
Upsher-smith Laboratories LLC2$49
Boston Scientific2$49
Acorda Therapeutics, Inc2$42
Corium, LLC2$42
Avion Pharmaceuticals2$40
Hospira, Inc.1$34
Mallinckrodt Enterprises LLC1$31
Microtransponder, Inc.1$28
Biohaven Pharmaceutical Holding Company Ltd.1$27
TG Therapeutics, Inc.1$24
Arbor Pharmaceuticals, Inc.1$20
Supernus Pharmaceuticals, Inc.1$18
Bristol Myers Squibb1$15
E.r. Squibb & Sons, L.L.C.1$13
W. L. Gore & Associates, Inc.1$11
Travere Therapeutics, Inc.5$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,746 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$498,907
Medicare patients
801
Services billed
3,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5031$479,252
NuplazidPimavanserin Tartrate24$114,853
AustedoDeutetrabenazine11$99,342
RexultiBrexpiprazole24$43,687
RytaryCarbidopa/Levodopa17$36,208
Memantine Hcl664$23,209
Aimovig AutoinjectorErenumab-Aooe26$19,261
Carbidopa-LevodopaCarbidopa/Levodopa557$13,817
Ajovy AutoinjectorFremanezumab-Vfrm12$12,398
Galantamine ErGalantamine Hbr63$8,954
Rasagiline Mesylate35$3,915
Donepezil Hcl473$3,847
Duloxetine Hcl151$3,321
Gabapentin270$3,067
Rivastigmine16$2,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$284$479,25231 claims
Acadia Pharmaceuticals IncNuplazid$737$114,85324 claims
Teva Pharmaceuticals USA, Inc.Austedo$589$99,34211 claims
Otsuka America Pharmaceutical, Inc.Rexulti$189$43,68724 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$608$39,25248 claims
Upsher-smith Laboratories LLCTopiramate$49$843155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →